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Adequate pain management in conditions of chronic 
inﬂ  ammation, such as rheumatoid arthritis, is a clinical 
challenge. While pain-relieving drugs such as cyclo-
oxygenase-inhibitors and opioids work well in the short 
term, long-term use is frequently associated with side 
eﬀ  ects. Th   e ongoing search for novel drugs for treatment 
of chronic pain is therefore well motivated. Proinﬂ  am  ma-
tory cytokines such as TNF, IL-1 and IL-6 are major 
mediators of joint inﬂ  ammation and destruction, and an 
increasing pool of preclinical data indicates that these 
cytokines are also key players in the generation and 
maintenance of pain. In the previous issue of Arthritis 
Research & Th  erapy, Boettger and colleagues focus on 
IL-6 and report that this cytokine plays a signiﬁ  cant role 
in arthritis-induced joint pain [1].
IL-6 is a multifunctional cytokine, with proinﬂ  amma-
tory and other regulatory properties. IL-6 exerts its eﬀ  ect 
on target cells by binding to the IL-6 speciﬁ  c membrane 
receptor (IL-6R), which activates the transducer glyco-
protein 130 (gp130), the second subunit of the IL-6R 
complex. Neurons are devoid of membrane-bound IL-6R, 
but these cells can still react to IL-6 when IL-6 is bound 
to the soluble form of IL-6R. Th  e IL-6/soluble IL-6R 
complex activates gp130, which is expressed on most 
cells, including neurons. While the functional role of 
gp130 expressed on neurons is not well understood, this 
protein has been linked to sensitization of pain-sensing 
nerves through activation of phosphoinositide 3-kinase, 
protein kinase C-delta and Janus kinase/signal transducer 
and activator of transcription 3 signaling pathways and 
through regulation of the pain-activated ion channel 
TRPV1 [2,3]. Using soluble glycoprotein 130 (sgp130), 
which binds and inactivates IL-6, Boettger and colleagues 
made several important ﬁ  ndings utilizing a rat model of 
antigen-induced arthritis.
First, the authors report that intraarticular adminis-
tration of sgp130 attenuates arthritis-induced pain. Th  is 
is an important ﬁ  nding as it suggests that IL-6 is a pain 
mediator – not only following nerve injury and tumor 
growth as has been reported earlier [2,3], but also 
subsequent to inﬂ  ammatory arthritis. Th  e  pain-relieving 
(antinociceptive) eﬀ  ect of local versus systemic injections 
of sgp130 was investigated, and, surprisingly, intra-
articular injection of gp130 to the knee joint had a greater 
antinociceptive eﬀ   ect than intraperitoneal injections. 
Th  is may be interpreted as local IL-6 in the joint being 
crucial for the nociceptive response, while circulating 
IL-6 is not. In such a case, one would expect a higher 
dose of systemic spg130 than used in Boettger and 
colleagues’ study to have similar pain-relieving eﬀ  ects, 
given that it reaches the joint in high enough 
concentrations.
From a clinical perspective it is critical that a pain-
relieving drug has the ability to reverse already-
established hypersensitivity, particularly in conditions 
such as arthritis where pain often is what brings the 
patient to seek medical attention. In the work presented 
by Boettger and colleagues, intraperitoneal post-treat-
ment only decreased stimulus-evoked pain responses 
while intraarticular pretreatment had a broad antinoci-
ceptive eﬀ   ect, also normalizing weight bearing, loco-
motion and gait – measures thought to indirectly reﬂ  ect 
ongoing pain. Because the routes of administration were 
diﬀ   erent in the pretreatment versus post-treatment 
comparison (intra  articular versus intraperitoneal, respec-
tively), further studies are warranted to determine 
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administrated during active arthritis. Th  is  determination 
is particularly important from the aspect of the antigen-
induced arthritis model being predictive of the human 
condition, as clinical studies have shown that rheumatoid 
arthritis patients treated with mono  clonal IL-6R antibody 
score lower on the pain visual analog scale and report a 
reduced number of tender joints [4].
Another noteworthy ﬁ  nding is that while one injection 
of sgp130 into the joint had an antinociceptive eﬀ  ect that 
lasted several days, no concurrent reduction of the joint 
inﬂ   ammation was observed. Blocking IL-6-mediated 
signaling, even in the presence of other factors that 
continuously drive the inﬂ  ammatory process, is therefore 
suﬃ     cient to bring the nociceptive thresholds back 
towards normal levels. In support of this notion, it has 
been demonstrated that IL-6 can trigger activation of 
pain ﬁ  bers in the absence of inﬂ  ammation. Exposure to 
IL-6 sensitizes both peripheral and spinal sensory 
neurons by electrophysiological measures [5-7], and 
applica  tion of IL-6 to the peripheral nerve or into the 
cerebrospinal ﬂ   uid evokes long-lasting pain behavior 
[7,8], indicating that the IL6/soluble IL-6R complex may 
be acting directly on neurons. Th  is does not exclude, 
however, the fact that IL-6 is also involved in the 
regulation of pain processing through actions on non-
neuronal cells. For example, IL-6 is elevated in the spinal 
cord subsequent to peripheral nerve injury in rats, which 
has been linked to microglia activation and associated 
neuropathic pain [3,8].
Finally, Boettger and colleagues found that although 
sgp130 failed to attenuate joint inﬂ  ammation,  bone 
erosion was reduced in the antigen-induced arthritis 
model. Th  e structure-sparing eﬀ  ect of sgp130 is in line 
with recent work showing that IL-6R inhibition blocks 
osteoclast formation in vitro and in vivo, independent of 
the anti-inﬂ  ammatory eﬀ  ect [9], and that bone erosion is 
reduced in rheumatoid arthritis patients on IL-6 inhibitor 
monotherapy [10]. Th   e antinociceptive eﬀ  ect observed in 
the study by Boettger and colleagues was therefore 
possibly at least partly related to a prevention of joint 
destruction. Th  is observation highlights the need for 
gaining a better and more detailed understanding of how 
bone erosion aﬀ  ects the sensory system.
In summary, there are several potential sites and 
mechanisms through which IL-6 may drive pain in 
conditions such as rheumatoid arthritis. While there are 
still critical steps to take before adding IL-6 blockers to 
the list of painkillers, it is an intriguing thought that 
anticytokine therapies have the potential to become new 
tools for treatment of chronic pain.
Abbreviations
gp130, glycoprotein 130; IL, interleukin; IL-6R, IL-6 membrane receptor; 
sgp130, soluble glycoprotein 130; TNF, tumor necrosis factor; TRPV1, transient 
receptor potential cation channel, subfamily Vanilloid, member 1.
Competing interests
The author declares that she has no competing interests.
Acknowledgements
The present work was supported by the Swedish Research Council and the 
European Union Marie Curie International Reintegration Grant.
Published: 28 October 2010
References
1.  Boettger MK, Leuchtweis J, Kummel D, Gajda M, Brauer R, Schaible HG: 
Diff  erential eff  ects of locally and systemically administered soluble 
glycoprotein 130 on pain and infl  ammation in experimental arthritis. 
Arthritis Res Ther 2010, 12:R140.
2.  Andratsch M, Mair N, Constantin CE, Scherbakov N, Benetti C, Quarta S, Vogl 
C, Sailer CA, Uceyler N, Brockhaus J, Martini R, Sommer C, Zeilhofer HU, Müller 
W, Kuner R, Davis JB, Rose-John S, Kress M: A key role for gp130 expressed 
on peripheral sensory nerves in pathological pain. J Neurosci 2009, 
29:13473-13483.
3.  Dominguez E, Rivat C, Pommier B, Mauborgne A, Pohl M: JAK/STAT3 
pathway is activated in spinal cord microglia after peripheral nerve injury 
and contributes to neuropathic pain development in rat. J Neurochem 
2008, 107:50-60.
4.  Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock 
E, Woodworth T, Alten R: Eff  ect of interleukin-6 receptor inhibition with 
tocilizumab in patients with rheumatoid arthritis (OPTION study): 
a double-blind, placebo-controlled, randomised trial. Lancet 2008, 
371:987-997.
5.  Kawasaki Y, Zhang L, Cheng JK, Ji RR: Cytokine mechanisms of central 
sensitization: distinct and overlapping role of interleukin-1β, interleukin-6, 
and tumor necrosis factor-α in regulating synaptic and neuronal activity 
in the superfi  cial spinal cord. J Neurosci 2008, 28:5189-5194.
6.  Brenn D, Richter F, Schaible HG: Sensitization of unmyelinated sensory 
fi  bers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: 
an infl  ammatory mechanism of joint pain. Arthritis Rheum 2007, 56:351-359.
7.  Eliav E, Benoliel R, Herzberg U, Kalladka M, Tal M: The role of IL-6 and IL-1β in 
painful perineural infl  ammatory neuritis. Brain Behav Immun 2009, 
23:474-484.
8.  Lee KM, Jeon SM, Cho HJ: Interleukin-6 induces microglial CX3CR1 
expression in the spinal cord after peripheral nerve injury through the 
activation of p38 MAPK. Eur J Pain 2010, 14:682.e1-e12.
9.  Axmann R, Bohm C, Kronke G, Zwerina J, Smolen J, Schett G: Inhibition of 
interleukin-6 receptor directly blocks osteoclast formation in vitro and in 
vivo. Arthritis Rheum 2009, 60:2747-2756.
10.  Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, 
Murata N, van der Heijde D, Kishimoto T: Study of active controlled 
monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): 
evidence of clinical and radiographic benefi  t from an X ray reader-blinded 
randomised controlled trial of tocilizumab. Ann Rheum Dis 2007, 
66:1162-1167.
doi:10.1186/ar3138
Cite this article as: Svensson CI: Interleukin-6: a local pain trigger? Arthritis 
Research & Therapy 2010, 12:145.
Svensson Arthritis Research & Therapy 2010, 12:145 
http://arthritis-research.com/content/12/5/145
Page 2 of 2